| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 101.93 | 20.0% | 156.5% |
| Total Income | 101.93 | 20.0% | 156.5% |
| Expenditure | 59.02 | 7.5% | 192.3% |
| PBT | 38.73 | 30.4% | 90.3% |
| Net Profit | 25.99 | 32.7% | 31.1% |
| OPM | 42.10% | 7.86pp | 7.09pp |
| NPM | 25.50% | 4.80pp | 24.40pp |
| EPS | 0.33 | 31.3% | 13.8% |
CorMedix Reports Q2 2026 Financial Results with $101.9M Revenue and $26.0M Net Income
13 Aug 2026 · 13 Aug, 5:07 pm
Summary
CorMedix Inc. announced strong second quarter 2026 financial results, with consolidated revenue reaching $101.9 million, a significant increase from $39.7 million in the prior year period. The company reported a net income of $26.0 million and adjusted EBITDA of $58.7 million. Management expressed confidence in the full-year outlook, maintaining revenue guidance and raising adjusted EBITDA guidance, while also highlighting progress in pipeline development with an anticipated FDA submission for REZZAYO.
Key Highlights
- 1
CorMedix Inc. reported consolidated revenue of $101.9 million for the second quarter of 2026.
- 2
The company achieved a net income of $26.0 million and adjusted EBITDA of $58.7 million in Q2 2026.
- 3
DefenCath® sales contributed $66.1 million in the second quarter, with the acquired Melinta portfolio adding $35.8 million.
- 4
CorMedix maintains its full-year 2026 consolidated revenue guidance of $325 to $345 million and raises full-year adjusted EBITDA guidance to $125 to $140 million.
- 5
The company anticipates an FDA submission for an expanded indication of REZZAYO in the third quarter of 2026.
- 6
Cash and short-term investments totaled $256.7 million at June 30, 2026, providing ample resources for operations.
Management Comments
Joseph Todisco
CorMedix delivered a strong second quarter, generating $101.9 million in consolidated revenue and $58.7 million of adjusted EBITDA, reflecting continued execution across our business. We remain confident in our full-year 2026 outlook and our revenue and adjusted EBITDA guidance as we continue to navigate the post-TDAPA reimbursement environment for DefenCath with discipline and focus. We also made meaningful progress across our pipeline and expect the near-term submission of the REZZAYO sNDA for prophylaxis. With a strong balance sheet, meaningful cash position, and a disciplined capital allocation strategy, we believe CorMedix is well positioned to support our commercial priorities, advance high-value development programs, and create sustainable long-term value for shareholders.
Informational and educational content only. Not investment advice.